Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms

M. Usart, J. Stetka, D. Luque Paz, N. Hansen, Q. Kimmerlin, T. Almeida Fonseca, M. Lock, L. Kubovcakova, R. Karjalainen, H. Hao-Shen, A. Börsch, A. El Taher, J. Schulz, JC. Leroux, S. Dirnhofer, RC. Skoda

. 2024 ; 143 (24) : 2490-2503. [pub] 20240613

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24013518

Pegylated interferon alfa (pegIFN-α) can induce molecular remissions in patients with JAK2-V617F-positive myeloproliferative neoplasms (MPNs) by targeting long-term hematopoietic stem cells (LT-HSCs). Additional somatic mutations in genes regulating LT-HSC self-renewal, such as DNMT3A, have been reported to have poorer responses to pegIFN-α. We investigated whether DNMT3A loss leads to alterations in JAK2-V617F LT-HSC functions conferring resistance to pegIFN-α treatment in a mouse model of MPN and in hematopoietic progenitors from patients with MPN. Long-term treatment with pegIFN-α normalized blood parameters and reduced splenomegaly and JAK2-V617F chimerism in single-mutant JAK2-V617F (VF) mice. However, pegIFN-α in VF;Dnmt3aΔ/Δ (VF;DmΔ/Δ) mice worsened splenomegaly and failed to reduce JAK2-V617F chimerism. Furthermore, LT-HSCs from VF;DmΔ/Δ mice compared with VF were less prone to accumulate DNA damage and exit dormancy upon pegIFN-α treatment. RNA sequencing showed that IFN-α induced stronger upregulation of inflammatory pathways in LT-HSCs from VF;DmΔ/Δ than from VF mice, indicating that the resistance of VF;DmΔ/Δ LT-HSC was not due to failure in IFN-α signaling. Transplantations of bone marrow from pegIFN-α-treated VF;DmΔ/Δ mice gave rise to more aggressive disease in secondary and tertiary recipients. Liquid cultures of hematopoietic progenitors from patients with MPN with JAK2-V617F and DNMT3A mutation showed increased percentages of JAK2-V617F-positive colonies upon IFN-α exposure, whereas in patients with JAK2-V617F alone, the percentages of JAK2-V617F-positive colonies decreased or remained unchanged. PegIFN-α combined with 5-azacytidine only partially overcame resistance in VF;DmΔ/Δ mice. However, this combination strongly decreased the JAK2-mutant allele burden in mice carrying VF mutation only, showing potential to inflict substantial damage preferentially to the JAK2-mutant clone.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013518
003      
CZ-PrNML
005      
20240905133322.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood.2023020270 $2 doi
035    __
$a (PubMed)38493481
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Usart, Marc $u Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland $1 https://orcid.org/0009000245758029
245    10
$a Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms / $c M. Usart, J. Stetka, D. Luque Paz, N. Hansen, Q. Kimmerlin, T. Almeida Fonseca, M. Lock, L. Kubovcakova, R. Karjalainen, H. Hao-Shen, A. Börsch, A. El Taher, J. Schulz, JC. Leroux, S. Dirnhofer, RC. Skoda
520    9_
$a Pegylated interferon alfa (pegIFN-α) can induce molecular remissions in patients with JAK2-V617F-positive myeloproliferative neoplasms (MPNs) by targeting long-term hematopoietic stem cells (LT-HSCs). Additional somatic mutations in genes regulating LT-HSC self-renewal, such as DNMT3A, have been reported to have poorer responses to pegIFN-α. We investigated whether DNMT3A loss leads to alterations in JAK2-V617F LT-HSC functions conferring resistance to pegIFN-α treatment in a mouse model of MPN and in hematopoietic progenitors from patients with MPN. Long-term treatment with pegIFN-α normalized blood parameters and reduced splenomegaly and JAK2-V617F chimerism in single-mutant JAK2-V617F (VF) mice. However, pegIFN-α in VF;Dnmt3aΔ/Δ (VF;DmΔ/Δ) mice worsened splenomegaly and failed to reduce JAK2-V617F chimerism. Furthermore, LT-HSCs from VF;DmΔ/Δ mice compared with VF were less prone to accumulate DNA damage and exit dormancy upon pegIFN-α treatment. RNA sequencing showed that IFN-α induced stronger upregulation of inflammatory pathways in LT-HSCs from VF;DmΔ/Δ than from VF mice, indicating that the resistance of VF;DmΔ/Δ LT-HSC was not due to failure in IFN-α signaling. Transplantations of bone marrow from pegIFN-α-treated VF;DmΔ/Δ mice gave rise to more aggressive disease in secondary and tertiary recipients. Liquid cultures of hematopoietic progenitors from patients with MPN with JAK2-V617F and DNMT3A mutation showed increased percentages of JAK2-V617F-positive colonies upon IFN-α exposure, whereas in patients with JAK2-V617F alone, the percentages of JAK2-V617F-positive colonies decreased or remained unchanged. PegIFN-α combined with 5-azacytidine only partially overcame resistance in VF;DmΔ/Δ mice. However, this combination strongly decreased the JAK2-mutant allele burden in mice carrying VF mutation only, showing potential to inflict substantial damage preferentially to the JAK2-mutant clone.
650    _2
$a zvířata $7 D000818
650    12
$a DNA methyltransferasa 3A $x genetika $7 D000090205
650    12
$a Janus kinasa 2 $x genetika $x metabolismus $7 D053614
650    12
$a DNA-(cytosin-5-)methyltransferasa $x genetika $x metabolismus $7 D004248
650    12
$a interferon alfa $x farmakologie $7 D016898
650    _2
$a myši $7 D051379
650    12
$a myeloproliferativní poruchy $x genetika $x patologie $x farmakoterapie $x metabolismus $7 D009196
650    _2
$a lidé $7 D006801
650    12
$a chemorezistence $x genetika $7 D019008
650    12
$a hematopoetické kmenové buňky $x metabolismus $x patologie $x účinky léků $7 D006412
650    _2
$a buněčná sebeobnova $7 D000066673
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a polyethylenglykoly $x farmakologie $7 D011092
650    _2
$a rekombinantní proteiny $7 D011994
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stetka, Jan $u Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/0000000343012856
700    1_
$a Luque Paz, Damien $u University of Angers, Nantes Université, Centre Hospitalier Universitaire Angers, INSERM, Centre National de la Recherche Scientifique, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Angers, France $1 https://orcid.org/000000024523675X
700    1_
$a Hansen, Nils $u Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland
700    1_
$a Kimmerlin, Quentin $u Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland
700    1_
$a Almeida Fonseca, Tiago $u Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland
700    1_
$a Lock, Melissa $u Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland
700    1_
$a Kubovcakova, Lucia $u Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland
700    1_
$a Karjalainen, Riikka $u Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland
700    1_
$a Hao-Shen, Hui $u Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland
700    1_
$a Börsch, Anastasiya $u Department of Biomedicine, Bioinformatics, University of Basel and University Hospital Basel, Basel, Switzerland $u Swiss Institute of Bioinformatics, Basel, Switzerland
700    1_
$a El Taher, Athimed $u Department of Biomedicine, Bioinformatics, University of Basel and University Hospital Basel, Basel, Switzerland $u Swiss Institute of Bioinformatics, Basel, Switzerland $1 https://orcid.org/0000000324248476
700    1_
$a Schulz, Jessica $u Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
700    1_
$a Leroux, Jean-Christophe $u Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland $1 https://orcid.org/0000000156011292
700    1_
$a Dirnhofer, Stefan $u Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland
700    1_
$a Skoda, Radek C $u Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland $1 https://orcid.org/0000000236269496
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 143, č. 24 (2024), s. 2490-2503
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38493481 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133316 $b ABA008
999    __
$a ok $b bmc $g 2143373 $s 1225384
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 143 $c 24 $d 2490-2503 $e 20240613 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options